RVTY Revvity

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Health science solutions provider across two segments (Life Sciences and Diagnostics), serving drug discovery through clinical diagnostics in 160+ countries
• • Notable new products in FY2025: Phenologic.AI™ deep-learning imaging module, EnVision Nexus® plate reader, NeoLSD™ 7 Plex MS/MS kit (first IVD for 7 lysosomal disorders from single blood spot), and T-SPOT.Flex™ customizable ELISPOT kit
• • AI integration accelerated across portfolio: Pin-point® base editing expanded with Profluent AI-enhanced adenine deaminase editors; EUROPattern™ Classifier 2.4 AI-enhanced IFA software; Living Image™ Synergy AI multimodal imaging platform
• • ~11,000 employees globally as of Dec 28, 2025; ~80% based outside the US; ~4,000 covered by labor union/works council agreements
• • Great Place to Work certifications achieved across India, China, Poland, US, and Brazil (Euroimmun) in 2025, with improved US scores YoY — notable cultural milestone for a company mid-transformation from PerkinElmer rebrand

Management Discussion & Analysis

• • Revenue $2,856.1M in FY2025, up $101.1M (+4%) YoY; Diagnostics +5% ($68.5M), Life Sciences +2% ($32.5M)
• • Gross margin 54.8% vs 55.8%; operating margin decreased 10 bps; SG&A ratio 34.7% vs 36.1%
• • Best segment: Diagnostics revenue +5% to $1,424.9M; worst: Life Sciences margin 32.0% vs 33.4% (-139 bps), Diagnostics margin 24.2% vs 26.1% (-194 bps)
• • Operating cash flow $589.0M vs $665.0M; buybacks $820.8M; capex $73.5M; dividends $32.8M
• • Key risks: tariff impact ~$20M net on gross margin; Life Sciences Solutions goodwill ($4.5B) fair value only 10–20% above carrying value; capex planned higher in FY2026

Risk Factors

• • Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S.
• • U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments
• • Single/limited-source suppliers for critical raw materials with multi-year contracts carrying no minimum purchase requirements, creating supply disruption risk
• • $9.0B net intangible assets on balance sheet as of December 28, 2025 — impairment risk if Life Sciences or Diagnostics segments underperform
• • Substantial debt across multiple tranches (2026–2051 Notes) with covenants restricting dividends, asset sales, and M&A; loss of investment-grade rating triggers higher costs

What are the latest RVTY SEC filings in 2026?

Revvity (RVTY) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did RVTY file its most recent 10-K annual report?

Revvity (RVTY) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view RVTY 10-Q quarterly reports?

Revvity (RVTY)'s most recent 10-Q quarterly report was filed on May 12, 2026. SignalX displays every RVTY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has RVTY filed recently?

Revvity (RVTY)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find RVTY insider trading activity (Form 4)?

SignalX aggregates every RVTY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does RVTY file with the SEC?

Revvity (RVTY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RVTY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Revvity (RVTY).

What is RVTY's SEC CIK number?

Revvity (RVTY)'s SEC CIK (Central Index Key) number is 31791. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 31791 to look up all RVTY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find RVTY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Revvity (RVTY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.